Market Overview

Fulcrum Therapeutics Announces $80 Million Series B Financing


Proceeds will help advance lead program in facioscapulohumeral
muscular dystrophy (FSHD) and further support advancement of rare
disease-focused pipeline

, a company focused on discovering and developing small
molecule therapies to unlock gene control and treat serious genetic
diseases, today announced the closing of an $80 million Series B
financing. Proceeds from the financing will be used to advance Fulcrum's
lead program in facioscapulohumeral muscular dystrophy (FSHD) into
clinical testing, and to progress its pipeline of therapeutics for rare,
genetically-based neuromuscular, central nervous system and hematologic

The financing was led by Foresite Capital, with participation by
Fidelity, 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section
32, NS Investments, entities affiliated with Leerink Partners and
undisclosed institutional investors. Jim Tananbaum, M.D., of Foresite
Capital will join the Board of Directors at Fulcrum.

"We are delighted to have the support of this exceptional group of
investors as we continue to work towards our vision of bringing new
futures to patients and families affected by debilitating genetic
diseases," said Robert J. Gould, Ph.D., Fulcrum's President and Chief
Executive Officer. "This funding will provide crucial support as we move
rapidly towards the clinic with our lead drug candidate in FSHD and
further advance our pipeline of small molecule therapies."

Fulcrum is pioneering a small molecule, precision medicine approach to
address serious monogenic and prevalent diseases of gene misregulation.
By focusing on disease-causative genes, the company is unlocking
druggable mechanisms that regulate disease to develop a new generation
of therapies in various therapeutic areas. In partnership with the FSHD
Clinical Trial Research Network (CTRN), the company has initiated
clinical trial readiness studies in FSHD. The aim of the studies is to
standardize a set of tools and measurements for Fulcrum's future
clinical drug trials.

"Fulcrum is leading the way with their small molecule, precision
medicine approach to treating severe genetic diseases," said Dr.
Tananbaum. "We believe the convergence of biology and data science will
be the key to unlocking novel treatments for patients and families that
have run out of options. We look forward to supporting the Fulcrum team
as it works to advance its rare disease-focused pipeline."

About Fulcrum Therapeutics

Fulcrum Therapeutics is a biotechnology company developing new medicines
to deliver a new future to patients and their families by transforming
gene regulation in disease. Fulcrum's therapies are based on modulating
gene regulation via control of genetic on and off switches of disease
genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third
Rock Ventures in 2016 and named a "Fierce 15" company later that year.
For more information, please visit

About Foresite Capital

Foresite Capital is a multi-stage healthcare and life sciences
investment firm with $2.2 billion in assets under management. The firm
aims to address areas of great unmet medical need by funding and guiding
promising healthcare and life sciences businesses with transformative
products and services at all stages of their life cycles. Foresite
Capital takes a collaborative approach to investing with its portfolio
companies by providing a multidisciplinary team of scientists,
engineers, analysts, and clinicians who understand the unique business
models in healthcare. Foresite Capital is based in San Francisco with an
office in New York. For more information, please visit

View Comments and Join the Discussion!